3D Living Tissues

Project description

A bioprinted 3D lymph node model for drug discovery

More than 90 % of oncology drugs fail in clinical trials. This is attributed to the unreliable in vitro models used for drug discovery. The scope of the EU-funded 3DLT project is to bring to market a proprietary 3D bioprinting technology that uses live human cells to generate tissues that closely resemble their human counterparts. Researchers have developed a 3D lymph node as a platform for testing new immunotherapies against cancer. The project's work includes assessing the economic feasibility of bringing the product to market, and making the necessary industrial and commercial partnerships to reach this objective.

Fields of science

• medical and health sciences › basic medicine › pharmacology and pharmacy › drug discovery
• social sciences › sociology › industrial relations › automation
• medical and health sciences › clinical medicine › oncology
• medical and health sciences › basic medicine › immunology › immunotherapy

Programme(s)

• H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme
• H2020-EU.3. - PRIORITY 'Societal challenges
• H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies

Topic(s)

• EIC-SMEInst-2018-2020 - SME instrument

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-1

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

PROMETHEUS S.R.L.

Net EU contribution

€ 50 000,00

Address

Via Trento 30
43122 Parma
Italy

Region

Nord-Est › Emilia-Romagna › Parma

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

Non-EU contribution

€ 21 429,00